Daily news about corporate social responsibility, ethics and sustainability
Tags (19) : drug development
AsymBio Expands Biologics CDMO with New Shanghai R&D Center
07/27/2026 | Companies
AccPCC,
ADC,
AI-enabled platform,
analytical development,
antibodies,
antibody-drug conjugates,
AsymBio,
Asymchem Group,
biologics,
biologics development,
biologics manufacturing,
biopharmaceuticals,
biotech partnerships,
biotechnology,
CDMO,
cell line development,
chemistry manufacturing and controls,
clinical manufacturing,
CMC,
commercial manufacturing,
conjugation process,
contract development,
contract manufacturing,
downstream processing,
drug development,
drug product development,
Fengxian,
global biotech,
green building,
innovation,
life sciences,
low-carbon infrastructure,
manufacturing excellence,
PCC selection,
pharmaceutical manufacturing,
pharmaceutical research,
preclinical candidate,
process development,
R&D expansion,
R&D facility,
research and development,
scale-up manufacturing,
science to clinic,
Shanghai,
sustainable construction,
technology transfer,
translational research,
upstream processing
Decoy Therapeutics Reports Promising Ebola Activity for Broad-Spectrum Antiviral Candidate
07/27/2026 | Companies
antiviral platform,
antiviral therapy,
arenaviruses,
biotechnology,
biotechnology news,
broad-spectrum antivirals,
coronavirus,
D-MAV,
DCOY,
Decoy Therapeutics,
Democratic Republic of the Congo,
Designable Multi-Antivirals,
drug development,
Ebola,
Ebola Zaire virus,
emerging viruses,
FDA Tropical Disease Priority Review Voucher,
filoviruses,
IMP3ACT platform,
in vitro study,
infectious disease treatment,
infectious diseases,
Lassa fever virus,
Marburg virus,
pandemic preparedness,
pharmaceutical research,
Texas Biomedical Research Institute,
Uganda,
viral fusion machinery,
viral research
Yidu Tech Highlights AI’s Role in Accelerating Drug Development at Summer Davos 2026
06/25/2026 | Companies
AI agents in healthcare,
AI in medicine,
AI-powered healthcare,
artificial intelligence in healthcare,
biotechnology,
BruHealth,
Brunei healthcare,
clinical research,
clinical trial optimization,
clinical trials,
data sovereignty,
data standardization,
digital health,
digital transformation in healthcare,
disease knowledge graph,
drug development,
evidence-based medicine,
global health innovation,
global healthcare innovation,
Gong Yingying,
healthcare access,
healthcare AI,
healthcare analytics,
healthcare compliance,
healthcare data governance,
healthcare data infrastructure,
healthcare data management,
healthcare digitization,
healthcare ecosystem,
healthcare infrastructure,
healthcare innovation,
healthcare policy,
healthcare research,
healthcare technology,
healthcare transformation,
life sciences,
medical AI,
medical research,
medical technology,
Novartis,
patient recruitment,
pharmaceutical innovation,
pharmaceutical R&D,
pharmaceutical technology,
precision medicine,
real-world evidence,
Summer Davos,
Summer Davos 2026,
World Economic Forum,
Yidu Tech,
YiduCore
Vector Science & Therapeutics Partners With MPP Group LLC to Advance Peptide Therapeutics
05/11/2026 | Companies
analytical testing,
aseptic manufacturing,
biotechnology,
cGMP manufacturing,
clinical peptide applications,
contract manufacturing organization,
drug development,
FDA-registered facility,
MPP Group LLC,
peptide compounding,
peptide delivery systems,
peptide formulations,
peptide market,
peptide stability,
peptide therapeutics,
pharmaceutical manufacturing,
pharmaceutical-grade peptides,
physician-supervised therapeutics,
regulated drug manufacturing,
shelf-stable peptides,
therapeutic peptides,
transdermal drug delivery,
transdermal technology,
Vector Science & Therapeutics,
Wisconsin biotech
FDA Modernization Act 2.0 and the Future of Non-Animal Models
05/04/2026 | Companies
2D cell cultures,
3D human biology,
96-well functional platforms,
automated hardware,
automated recording,
biotechnology,
cardiac research,
contractile force analysis,
drug development,
Duchenne muscular dystrophy,
electrophysiology,
FDA Modernization Act 2.0,
fluorescence readouts,
high-throughput screening,
human-relevant data,
life sciences webinar,
NAMs,
neuromuscular research,
neurotoxin potency testing,
Non-Animal Models,
optogenetics,
organ-on-a-chip,
pharmaceutical industry,
predictive modeling,
quantitative analysis,
regulatory science,
safety pharmacology,
skeletal muscle research,
toxicology research
Lakewood-Amedex Appoints Joseph Tucker to Board After Nasdaq Listing
04/28/2026 | Companies
antibiotic resistance,
antimicrobial drugs,
biotech leadership,
biotechnology,
Bisphosphocin,
board of directors,
capital markets,
clinical trials,
clinical-stage biotech,
corporate governance,
diabetic foot ulcers,
drug development,
Enveric Biosciences,
healthcare innovation,
Joseph Tucker,
Lakewood-Amedex Biotherapeutics,
Nasdaq listing,
neurological disorders,
neuropsychiatric disorders,
Nu-3,
pipeline development,
small-molecule therapeutics,
strategic growth
Arcera–Fosun Pharma MoU to Boost Global Life Sciences & Neuroscience Innovation
04/28/2026 | Companies
Abu Dhabi,
Alzheimer’s disease,
Arcera Life Sciences,
biologics,
biotechnology,
biotechnology incubation,
cardiometabolic diseases,
cell therapy,
China,
drug development,
emerging markets,
Fosun Pharma,
gene therapy,
global healthcare,
healthcare infrastructure,
innovation,
international collaboration,
joint ventures,
licensing,
life sciences,
market access,
memorandum of understanding,
Middle East healthcare,
MoU,
neurodegenerative diseases,
neuroscience,
oncology,
pharmaceutical industry,
R&D,
radiopharmaceuticals,
rare diseases,
research and development,
siRNA therapies,
small molecules,
strategic partnership,
UAE,
Vision 2030
Mabwell Advances 6MW5311 Bispecific Antibody for AML and Blood Cancers
04/16/2026 | Companies
6MW5311,
acute myeloid leukemia,
AML,
biopharmaceuticals,
biotechnology,
bispecific antibody,
cancer research,
CD3,
chronic myelomonocytic leukemia,
clinical trials,
CMML,
cytotoxicity,
drug development,
FDA,
hematologic malignancies,
immune synapse,
immunotherapy,
IND application,
LILRB4,
Mabwell,
MM,
multiple myeloma,
NMPA,
oncology,
preclinical studies,
stem cell transplantation,
steric hindrance,
T cell engager,
targeted therapy,
TCE technology,
tumor inhibition
Jazz Pharmaceuticals Showcases Epilepsy and Narcolepsy Research at AAN 2026
04/09/2026 | Companies
AAN 2026,
American Academy of Neurology,
behavioral symptoms,
cannabidiol,
clinical research,
cognitive function,
Dravet syndrome,
drug development,
DUET study,
EpiCom study,
Epidiolex,
epilepsy,
Jazz Pharmaceuticals,
Lennox-Gastaut syndrome,
medical conference,
narcolepsy,
neurological disorders,
neuroscience,
patient care,
Phase 3 trial,
rare diseases,
refractory epilepsy,
sleep disorders,
treatment outcomes,
tuberous sclerosis complex,
Xywav
Insilico Medicine & ASKA Partner to Advance AI-Driven Treatments for Gynecological Diseases
03/25/2026 | Companies
adenomyosis,
AI drug discovery,
artificial intelligence in healthcare,
ASKA Pharmaceutical,
biotechnology,
clinical-stage research,
disease target identification,
drug development,
endometriosis,
generative AI,
gynecological diseases,
Insilico Medicine,
medical innovation,
PandaOmics,
pharmaceutical collaboration,
reproductive health,
TargetPro,
therapeutic targets,
uterine fibroids,
women’s health
Harbour BioMed Reports Positive Phase I Results for HBM9378 Antibody Therapy
03/23/2026 | Companies
antibody therapeutics,
biologics,
biotech innovation,
chronic obstructive pulmonary disease,
clinical research,
COPD,
drug development,
half-life extension,
Harbour BioMed,
HBM9378,
immune-oncology,
immunological disorders,
immunology,
Kelun-Biotech,
monoclonal antibody,
pharmacokinetics,
Phase I clinical trial,
respiratory medicine,
safety profile,
severe asthma,
SKB378,
TSLP inhibitor,
WIN378
Belief BioMed & Grand Life Sciences Partner to Advance Hemophilia A Gene Therapy in China
03/23/2026 | Companies
BBM-H803,
BBM-H901,
Belief BioMed,
biotech industry,
biotechnology partnership,
China healthcare,
clinical development,
commercialization rights,
drug development,
gene therapy,
Grand Life Sciences,
healthcare innovation,
hematology,
hemophilia A,
hemophilia treatment,
innovative therapies,
medical research,
pharmaceutical collaboration,
rare diseases
Vimgreen Secures IND Approval for VG081821 in NASH Treatment
03/18/2026 | Companies
A2A receptor antagonist,
adenosine signalling,
biotechnology,
China CDE,
clinical trials,
drug development,
fibrosis,
hepatology,
IND approval,
inflammation,
inverse agonist,
lipophagy,
liver disease,
MASH,
metabolic disorders,
metabolic dysfunction associated steatohepatitis,
NASH,
non alcoholic steatohepatitis,
Parkinsons disease,
Phase II trial,
resmetirom,
semaglutide,
steatosis,
VG081821,
Vimgreen Pharmaceuticals
HotSpot Therapeutics, Inc. to Present IRF5 Lupus Preclinical Data at European Lupus Meeting 2026
02/26/2026 | Companies
Syngene Extends Strategic Partnership with Bristol Myers Squibb Through 2035
01/21/2026 | Companies
biopharmaceutical industry,
Bristol Myers Squibb,
cardiovascular research,
clinical biomarkers,
clinical trials,
contract research organization,
CRDMO,
drug development,
drug discovery,
drug metabolism and pharmacokinetics,
end-to-end solutions,
fibrosis research,
global pharma,
immunology research,
innovation in healthcare,
integrated services,
life sciences,
manufacturing excellence,
oncology research,
patient-centric research,
pharmaceutical development,
pharmaceutical manufacturing,
preclinical development,
R&D partnership,
research collaboration,
strategic partnership,
Syngene International,
translational sciences
Ribo Life Science Lists on HKEX, Raising HKD 1.8 Billion in siRNA IPO
01/09/2026 | Companies
biopharmaceutical industry,
biotechnology innovation,
capital markets,
Chinese biotech,
clinical trials,
cornerstone investors,
drug development,
global offering,
healthcare innovation,
HKEX IPO,
Hong Kong Stock Exchange,
investor confidence,
liver-targeted delivery,
research and development,
Ribo Life Science,
RiboGalSTAR,
RNA interference,
siRNA therapeutics
Gilead Sciences Leads in Innovation & Responsibility
03/20/2025 | Companies
biopharmaceuticals,
corporate responsibility,
drug development,
employee empowerment,
Foster City California,
Gilead Sciences,
global health,
global operations,
healthcare,
innovative medicines,
life-threatening illnesses,
medical innovation,
medical research,
responsible business,
top biopharma companies
Enhancing Diversity in Clinical Trials: Why It Matters for Drug Development
01/15/2025 | Companies
clinical research,
clinical trial barriers,
clinical trial diversity,
clinical trial inclusion,
clinical trial participation,
clinical trial statistics,
clinical trials,
cultural competency,
diversity in clinical trials,
drug development,
ethnic diversity,
FDA guidelines,
health equity,
healthcare access,
healthcare disparities,
healthcare diversity,
medical research,
patient-centered development,
pharmaceutical industry,
Teva,
underrepresented groups
Brii Biosciences Acquires Full Rights to BRII-179 for HBV Cure Advancement
01/01/2025 | Companies
biotechnology,
Brii Biosciences,
BRII-179,
clinical trials,
combination therapies,
drug development,
elebsiran,
ENRICH study,
functional cure,
HBV,
healthcare innovation,
Hepatitis B Virus,
intellectual property acquisition,
know-how,
patents,
PEG-IFNα,
Phase 2b study,
shareholder value,
unmet medical needs,
VBI Vaccines
Companies
Most Popular Now
Environment News
Compliance
Want to write a piece for Daily CSR? Please contact us by email at editor[@]dailycsr.com